Last $29.75 USD
Change Today +1.10 / 3.84%
Volume 1.0M
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:32 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Stanley T. Crooke M.D., Ph.D.

Founder, Executive Chairman, Chief Executive Officer, President, Chairman of Science/Medical Committee and Member of Agenda Committee, Isis Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 14 board members in 3 different organizations across 7 different industries.

See Board Relationships
69$2,758,536
As of Fiscal Year 2013

Background*

Dr. Stanley T. Crooke, M.D., Ph.D. has been an Executive Chairman of Isis Pharmaceuticals, Inc. since February 1991, and has been its Chief Executive Officer since January 1989. Dr. Crooke serves as the President of Isis Pharmaceuticals, Inc. He serves as an Editor-in-Chief of Current Opinion in Anticancer Drugs and Section Editor for Biologicals and Immunologicals for Expert Opinion on Investigational Drugs. Dr. Crooke founded Isis Pharmaceuticals, Inc. in 1989 and ...

Read Full Background

Corporate Headquarters*

2855 Gazelle Court
Carlsbad, California 92010

United States

Phone: 760-931-9200
Fax: --

Board Members Memberships*

Former Director
Director
Former Non-executive Director
Director
Director
1989-Present
Founder, Executive Chairman, Chief Executive Officer, President, Chairman of Science/Medical Committee and Member of Agenda Committee
1992-N/A
Former Chairman of the Board
1992-N/A
Former Director
1996-2005
Former Director
1999-2002
Former Director
2001-2006
Former Non Executive Director and Member of Remuneration Committee
2009-2012
Former Director and Member of Compensation Committee

Education*

PhD
Baylor College of Medicine
MD
Baylor College of Medicine
BS
Butler University

Other Affiliations*

Annual Compensation*

Salary$735,169
Bonus$803,907
Total Annual Compensation$1,539,076

Stock Options*

Restricted Stock Awards$325,971
All Other Compensation$15,752
Exercised Options509,235
Exercised Options Value$9,272,872
Exercisable Options407,076
Exercisable Options Value$11,443,908
Unexercisable Options224,566
Unexercisable Options Value$6,217,238
Total Value of Options$26,934,018
Total Number of Options1,140,877

Total Compensation*

Total Annual Cash Compensation$1,554,828
Total Short Term Compensation$1,539,076
Other Long Term Compensation$341,723
Total Calculated Compensation$2,758,536
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $29.74 USD +1.09

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Secretary
Enzon Pharmaceuticals Inc.
$428.5K
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
A$249.8K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.